Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival-Reference-Cited by-全球学者库

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival

Published:2018-09-11 Issue:12 Volume:7 Page:e1509820
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Sobral-Leite Marcelo¹²^ORCID,Van de Vijver Koen³^ORCID,Michaut Magali⁴^ORCID,van der Linden Rianne³,Hooijer Gerrit K.J.⁵,Horlings Hugo M.³^ORCID,Severson Tesa M.⁴^ORCID,Mulligan Anna Marie⁶⁷,Weerasooriya Nayana⁸^ORCID,Sanders Joyce³^ORCID,Glas Annuska M⁹^ORCID,Wehkamp Diederik⁹,Mittempergher Lorenza⁹,Kersten Kelly¹⁰,Cimino-Mathews Ashley¹¹,Peters Dennis¹²,Hooijberg Erik³^ORCID,Broeks Annegien¹²,van de Vijver Marc J.⁵,Bernards Rene⁴^ORCID,Andrulis Irene L.⁷¹³¹⁴,Kok Marleen¹⁵¹⁶^ORCID,de Visser Karin E.⁹^ORCID,Schmidt Marjanka K.¹^ORCID

Affiliation:

1. Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands

2. Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brasil

3. Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands

4. Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands

5. Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands

6. Laboratory Medicine Program, University Health Network, Toronto, ON, Canada

7. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

8. University Health Network, Toronto, ON, Canada

9. Agendia NV, Science Park, Amsterdam, The Netherlands

10. Division of Tumor Biology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands

11. Departments of Pathology and Oncology, The Johns Hopkins Hospital, Baltimore, USA

12. Core Facility Molecular Pathology and Biobanking, Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands

13. Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada

14. Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

15. Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

16. Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Funder

European Commission

Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior

HHS | National Institutes of Health

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1509820

Reference56 articles.

1. Clinical relevance of host immunity in breast cancer: from TILs to the clinic

2. The immune system and hormone-receptor positive breast cancer: Is it really a dead end?

3. Elements of cancer immunity and the cancer–immune set point

4. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

5. The PD-1–PD-L pathway in immunological tolerance

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overexpression of ADAM10 correlates with poor prognosis and immune infiltrates in breast cance;2024-01-25

2. Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial;Journal for ImmunoTherapy of Cancer;2024-01

3. The Programmed Cell Death Ligand 1 and Lipocalin 2 Expressions in Primary Breast Cancer and Their Associations with Molecular Subtypes and Prognostic Factors;Breast Cancer: Targets and Therapy;2024-01

4. Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis;ESMO Open;2023-12

5. PDL1-Based Nomogram May Be of Potential Clinical Utility for Predicting Survival Outcome in Stage III Breast Cancer;Breast Cancer: Targets and Therapy;2023-10